Although targeted therapies of IDH1, IDH2, EGFR, and FGFR are under investigation with promising preliminary results (19–21), more therapies, other than chemotherapy, should be discovered from basic studies to cover a wider scope of CCA patients. This evidence concerns the gene EGFR and cholangiocarcinoma.